“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitorsRead More
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialRead More
Nodular lymphocyte predominant Hodgkin lymphoma: Advances in disease biology, risk stratification and treatmentRead More
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyRead More
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapiesRead More
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialRead More
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyRead More